WO2005094813A1 - 腎疾患用薬剤 - Google Patents
腎疾患用薬剤 Download PDFInfo
- Publication number
- WO2005094813A1 WO2005094813A1 PCT/JP2005/006836 JP2005006836W WO2005094813A1 WO 2005094813 A1 WO2005094813 A1 WO 2005094813A1 JP 2005006836 W JP2005006836 W JP 2005006836W WO 2005094813 A1 WO2005094813 A1 WO 2005094813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- improving
- prognosis
- agent
- leucine
- isoleucine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention relates to an agent for improving the prognosis of life in renal diseases, particularly in chronic renal failure.
- Therapies include, for example, pharmacotherapy to control symptoms, such as antihypertensive diuretics, or diet and lifestyle management, but pharmacotherapy is useful for preventing the progression and worsening of renal impairment. Although there is a problem of side effects.
- low-protein diets which are used as a diet, are also useful for preventing the progression and deterioration of renal damage, but may worsen the nutritional status of patients, making it difficult to control and prolonging the survival prognosis of patients. Sometimes it makes it worse. Therefore, there is a need for a drug that has weak side effects and is useful for improving the prognosis of life.
- An object of the present invention is to provide a life prognosis improving agent for renal disease.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and found that a composition containing three types of branched chain amino acids of isoleucine, leucine, and palin as active ingredients improves life expectancy, anemia, and the like in chronic renal failure model rats.
- the present inventors have found that there is an effect of improving the prognosis of life, such as improvement of renal function decline, and have completed the present invention.
- the present invention is as follows.
- a prognosis improving agent for renal disease patients comprising at least one kind of branched-chain amino acid selected from isoleucine, leucine and palin.
- the life prognosis improving agent according to (1) which is a hemoglobin level improving agent.
- the life prognosis improver according to the above (1) which is a hematocrit improver.
- the agent for improving prognosis of life according to (1) which is an agent for improving renal function decline.
- the life prognosis improving agent according to the above (1) which is a blood creatine level improving agent.
- a method for improving the life prognosis of a renal disease patient comprising administering to the patient an effective amount of at least one kind of branched-chain amino acid selected from isoleucine, leucine, and parin.
- a method for improving the prognosis of a patient with renal disease which comprises administering an effective amount of isoleucine, leucine, and palin to the patient.
- isoleucine, leucine, and parin for producing a prognosis improving agent for renal disease patients comprising at least one kind of branched-chain amino acid selected from isoleucine, leucine, and palin.
- a pharmaceutical composition comprising at least one kind of branched-chain amino acid selected from isoleucine, leucine, and palin for improving the prognosis of a patient with renal disease.
- a pharmaceutical composition comprising isoleucine, leucine, and palin for improving the prognosis of a patient with renal disease.
- a food for improving the prognosis of life for patients with renal disease which comprises at least one kind of branched-chain amino acid selected from isoleucine, leucine, and palin.
- FIG. 1 is a graph showing the survival rate of 56 partial nephrectomized chronic renal failure model rats given a diet supplemented with branched-chain amino acids.
- FIG. 2 is a graph showing the effect of the administration of branched-chain amino acids on hemoglobin levels in a 5Z6 partially nephrectomized chronic renal failure model rat.
- FIG. 3 is a graph showing the effect of administration of branched-chain amino acids on hematocrit in 5/6 partial nephrectomy chronic renal failure model rats.
- FIG. 4 is a graph showing the effects of administration of branched-chain amino acids on creatinine levels in a 5Z6 partially nephrectomized chronic renal failure model rat.
- the prognosis of life in the present invention refers to the progress of a disease state and the life expectancy of a disease patient.
- improving the prognosis of life refers to improving the progress of the disease state of a diseased patient.
- the “life prognosis improving agent” in the present invention refers to an agent that improves the course of a diseased patient.
- examples of the condition of a renal disease patient improved by the life prognosis improving agent of the present invention include life expectancy, decreased renal function, and anemia.
- Dry weight target body weight, appropriate body weight, dry body weight
- obesity BMI, body mass index, body fat percentage
- lean body mass lean body mass
- meal Improvements in dietary protein intake, dietary caloric intake, and blood albumin level are excluded in the present invention.
- Renal disease includes chronic renal failure, acute renal failure, nephrotic syndrome, pyelonephritis, etc. Among them, it is particularly useful for patients with chronic renal failure.
- the agent for improving the prognosis of life of the present invention is useful for improving the life expectancy of patients with renal disease (prolonging the life and improving the survival rate).
- anemia includes iron deficiency anemia, anemia associated with chronic anemia, sideroblastic anemia, and thalassemia.
- Atransferrinemia, renal anemia, hemolytic anemia, aplastic anemia, erythroblastosis, myelodysplastic syndrome, anemia associated with chronic diseases, leukemia, megaloblastic anemia, hepatic impairment, hypothyroidism Is known as a causative disease, especially if renal dysfunction is ruled out in patients with renal disease, it is defined as renal anemia, and hemoglobin (hematocrit) ) Refers to the state where the value has decreased.
- the agent for improving prognosis of life of the present invention is more preferably useful for improving renal anemia.
- the agent for improving the prognosis of life of the present invention is useful for improving renal function deterioration in patients with renal disease.
- renal function deterioration means abnormalities in renal hemofiltration and urine production, Parameters such as blood creatine and BUN (blood urea nitrogen) The state where the value etc. is rising. That is, the improvement of renal function deterioration means improvement of these figures.
- the branched-chain amino acid as an active ingredient of the present invention is used as a life expectancy improving agent, an anemia improving agent, a hemoglobin level improving agent, a hematocrit level improving agent, a renal function lowering improving agent, and a blood creatinine level improving agent. Is also useful. These are especially useful for patients with renal disease.
- Chronic renal failure includes chronic glomerulonephritis, diabetic nephropathy, renal sclerosis, etc., whose serum creatinine level is 2 mg / dl or more or BUN is 20 mg / dl or more.
- the presence or absence of dialysis such as hemodialysis and peritoneal dialysis in chronic renal failure patients does not matter, but treatment after introduction of dialysis is preferred.
- the prognosis for life is worse if the albumin level is less than 4. Og / dl and the hematocrit is less than 30%. It is useful for patients with albumin level less than 4. Og / dl and hematocrit less than 30% as of December 31, 2001).
- the agent for improving the prognosis of life of the present invention can be administered to animals (for example, mammals such as humans, monkeys, rabbits, pomas, dogs, cats, rabbits, rats, and mice). Animals include livestock, poultry, and laboratory animals. The mode of administration to animals other than humans may be addition to feed.
- animals for example, mammals such as humans, monkeys, rabbits, pomas, dogs, cats, rabbits, rats, and mice.
- Animals include livestock, poultry, and laboratory animals.
- the mode of administration to animals other than humans may be addition to feed.
- the isoleucine, leucine and palin which are the active ingredients (branched chain amino acids) of the present invention, can be used in any of the isomers, D-forms and DL-forms, but are preferably L-forms and DL-forms. More preferably, it is the L-form.
- isoleucine, leucine and valine can be used not only in a free form but also in a salt form. Examples of the salt form include an acid addition salt and a salt with a base. It is preferable to select a salt of isoleucine, leucine and palin which is acceptable as a pharmaceutical or food or drink.
- Acids which form salts acceptable as pharmaceuticals or foods and drinks by adding to isoleucine, leucine and palin, respectively include, for example, inorganic salts such as hydrogen chloride, hydrogen bromide, sulfuric acid, phosphate, acetic acid, lactic acid, Acid, tartaric acid, maleic acid, fuma Organic salts such as vac acid or monomethyl sulfate.
- inorganic salts such as hydrogen chloride, hydrogen bromide, sulfuric acid, phosphate, acetic acid, lactic acid, Acid, tartaric acid, maleic acid, fuma
- Organic salts such asizic acid or monomethyl sulfate.
- isoleucine, leucine, and palin bases that are acceptable as pharmaceuticals or foods and drinks include, for example, hydroxides or carbonates of metals such as sodium, potassium, and calcium, and inorganic bases such as ammonia.
- the agent for improving the prognosis of life of the present invention only needs to contain at least one of isoleucine, leucine and valine as a branched-chain amino acid, and preferably contains all of isoleucine, leucine and parin. More preferably, the weight ratio of isoleucine, leucine, and valine is 1: 1.0 to 3.0: 0.5 to: 1.5. More preferably, the weight ratio of isoleucine, leucine, and phosphorus is 1: 1.5 to 2.5: 0.8 to 1.3. The most preferred weight ratio is 1: 2.0: 1.2.
- the administration method of the drug of the present invention may be oral administration, parenteral administration (ingestion) such as infusion administration, injection administration (intravenous administration) or the like, and is not particularly limited.
- parenteral administration such as infusion administration, injection administration (intravenous administration) or the like
- the active ingredient is an amino acid
- oral administration is possible.
- the dose (intake) of the agent for improving the prognosis of life of the present invention when administered orally varies depending on the condition, age, and administration method of the patient to be administered.
- 30. O g, leucine 1.0 to 30. O g, and phosphorus 1.0 to 30.0 g.
- the total daily dose for an adult is preferably 1.0 g to 50 g. More preferably, the total dose per adult per day is 3.0 to 30 g. More preferably, it is 4.0 to 25 g.
- parenteral administration such as drip administration, injection administration (intravenous administration), etc.
- the dose (intake) can be administered in the order of 10 to 20 times lower.
- Isoleucine, leucine, and valine which are the branched-chain amino acids of the present invention, may be formulated alone or in a combination of any two, or may be formulated to contain all of them. When they are separately formulated and administered, their administration route and dosage form may be the same or different, and the administration timing of each may be simultaneous or separate. . It will be determined appropriately depending on the type and effect of the concomitant drug.
- weight ratio indicates the weight ratio of each component in the preparation.
- each branched-chain amino acid of isoleucine, leucine, and valine is contained in one drug product, it is the ratio of the respective contents, and each of the branched-chain amino acids is used alone or in combination of any two.
- each of the branched-chain amino acids is used alone or in combination of any two.
- the ratio of the weight of each branched-chain amino acid contained in each formulation When contained in a formulation, it is the ratio of the weight of each branched-chain amino acid contained in each formulation.
- the agent for improving life prognosis of the present invention can be administered orally or as an injection.
- Oral preparations include granules, fine granules, tablets, powders, capsules, chewables, liquids, suspensions, etc., and injection preparations for general pharmaceutical preparations such as those for direct intravenous injection and infusion. Mold can be adopted.
- the agent for improving prognosis of life of the present invention can be formulated by a conventional method.
- a conventional method for example, lactose, glucose, D-mannitol, starch, crystalline cellulose, calcium carbonate, kaolin, gelatin, etc., carriers, solvents, solubilizing agents, isotonic agents, etc.
- Additives can be appropriately compounded.
- the agent for improving the prognosis of life of the present invention can be used particularly as a drug (including a drug for improving the prognosis of life in a patient with renal disease, a nutrient, etc.) or a food or drink (including a health food, a dietary supplement, etc.).
- a drug including a drug for improving the prognosis of life in a patient with renal disease, a nutrient, etc.
- a food or drink including a health food, a dietary supplement, etc.
- the active ingredient is an amino acid
- it has excellent safety and can be easily used in the form of food and drink.
- It is also possible to provide such foods and drinks as health-functional foods.Foods and drinks with a label indicating that they are used for the prevention and treatment of visceral pain, and Foods, etc. are included.
- the above preparations may be used as they are.
- the form is not particularly limited, and only the branched-chain amino acids of the drug for improving the prognosis of
- the survival rate in the 56-part nephrectomized chronic renal failure model rat was higher in the group supplemented with branched-chain amino acids than in the group supplemented with casein. This From the results, it has been clarified that the addition of the branched-chain amino acid of the present invention is effective for improving the prognosis of renal disease life.
- the hemoglobin value in the rats with a 5/6 partial nephrectomy and chronic renal failure model was higher in the branched chain amino acid administration group than in the control administration group.
- Yotsu thus, it was revealed that the addition of the 'branched-chain amino acid' of the present invention is involved in the effect of improving the * ⁇ *-g: 5! -Vis value, ie, the effect of improving anemia.
- the drug provided by the present invention which contains at least one kind of branched-chain amisoic acid selected from the group consisting of i-so-i.
- Is useful because it can improve Furthermore, the drug can also improve life expectancy in renal diseases, anemia, and decreased renal function.
- the present prognosis-improving agent is advantageous as a pharmaceutical product because it has high safety and almost no side effects, since it contains amino acids as an active ingredient.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511898A JPWO2005094813A1 (ja) | 2004-03-31 | 2005-03-31 | 腎疾患用薬剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004105457 | 2004-03-31 | ||
JP2004-105457 | 2004-03-31 | ||
JP2005004051 | 2005-01-11 | ||
JP2005-004051 | 2005-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094813A1 true WO2005094813A1 (ja) | 2005-10-13 |
Family
ID=35063494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006836 WO2005094813A1 (ja) | 2004-03-31 | 2005-03-31 | 腎疾患用薬剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005094813A1 (ja) |
WO (1) | WO2005094813A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072663A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | ステロイド療法における副作用の改善・抑制用組成物 |
WO2010064714A1 (ja) | 2008-12-05 | 2010-06-10 | 味の素株式会社 | 栄養組成物 |
ES2521841A1 (es) * | 2013-05-08 | 2014-11-13 | Instituto De Investigación Sanitaria - Fundación Jiménez Díaz | Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982000411A1 (en) * | 1980-07-31 | 1982-02-18 | G Blackburn | Novel amino acid preparation and therapy for treatment of stress and injury |
JPS58165774A (ja) * | 1982-03-29 | 1983-09-30 | Ajinomoto Co Inc | 飲料組成物 |
JPS61181359A (ja) * | 1984-12-12 | 1986-08-14 | ボエリンゲル・ビオケミア・ロビン・エツセ・ピ−・ア− | アミノ酸をベースとする栄養ペレット |
JPH03502805A (ja) * | 1988-12-22 | 1991-06-27 | ベルターマン ハーゲン | 腎保護持続注入液 |
JP2003171271A (ja) * | 2001-09-26 | 2003-06-17 | Ajinomoto Co Inc | 耐糖能異常用薬剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2599593B2 (ja) * | 1986-06-26 | 1997-04-09 | 株式会社 大塚製薬工場 | 腎不全用アミノ酸輸液 |
JP2534139B2 (ja) * | 1989-10-09 | 1996-09-11 | 株式会社大塚製薬工場 | 腎不全用経口アミノ酸製剤 |
JPH04159219A (ja) * | 1990-10-23 | 1992-06-02 | Otsuka Pharmaceut Factory Inc | 腎不全用経口アミノ酸製剤 |
-
2005
- 2005-03-31 JP JP2006511898A patent/JPWO2005094813A1/ja active Pending
- 2005-03-31 WO PCT/JP2005/006836 patent/WO2005094813A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982000411A1 (en) * | 1980-07-31 | 1982-02-18 | G Blackburn | Novel amino acid preparation and therapy for treatment of stress and injury |
JPS58165774A (ja) * | 1982-03-29 | 1983-09-30 | Ajinomoto Co Inc | 飲料組成物 |
JPS61181359A (ja) * | 1984-12-12 | 1986-08-14 | ボエリンゲル・ビオケミア・ロビン・エツセ・ピ−・ア− | アミノ酸をベースとする栄養ペレット |
JPH03502805A (ja) * | 1988-12-22 | 1991-06-27 | ベルターマン ハーゲン | 腎保護持続注入液 |
JP2003171271A (ja) * | 2001-09-26 | 2003-06-17 | Ajinomoto Co Inc | 耐糖能異常用薬剤 |
Non-Patent Citations (3)
Title |
---|
HIROSHIGE K. ET AL: "Oral supplementation of branched-chain amino acid improves nutritional status in eldery patients on chronic haemodialysis.", NEPHROLOGY DIALYSIS TRANSPLANTATION., vol. 16, 2001, pages 1856 - 1862, XP002989603 * |
SHIKKAN J.: "Igaku no Ayumi, Ishiyaku Pub.Inc.", vol. 183, part 3 1997, article KIN N.: "HDF no Tekio to Koka", pages: 314 - 319, XP002997003 * |
SHIKKAN J.: "separate volume Igaku no Ayumi,state of arts, 1st edition, 1st print.", vol. 1, part 1 1992, ISHIYAKU PUB.INC., article KUMANO K.: "Toseki Ryoho to Eiyo Jotai.", pages: 173 - 175, XP002997004 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008072663A1 (ja) * | 2006-12-12 | 2008-06-19 | Ajinomoto Co., Inc. | ステロイド療法における副作用の改善・抑制用組成物 |
CN103120655A (zh) * | 2006-12-12 | 2013-05-29 | 味之素株式会社 | 用于改善/预防类固醇治疗中的不利副作用的组合物 |
EP2606882A1 (en) * | 2006-12-12 | 2013-06-26 | Ajinomoto Co., Inc. | Composition for amelioration/prevention of adverse side effect in steroid therapy |
JP5293189B2 (ja) * | 2006-12-12 | 2013-09-18 | 味の素株式会社 | ステロイド療法における副作用の改善・抑制用組成物 |
JP2013216671A (ja) * | 2006-12-12 | 2013-10-24 | Ajinomoto Co Inc | ステロイド療法における副作用の改善・抑制用組成物 |
JP2015166352A (ja) * | 2006-12-12 | 2015-09-24 | 味の素株式会社 | ステロイド療法における副作用の改善・抑制用組成物 |
CN103120655B (zh) * | 2006-12-12 | 2016-06-01 | 味之素株式会社 | 用于改善/预防类固醇治疗中的不利副作用的组合物 |
WO2010064714A1 (ja) | 2008-12-05 | 2010-06-10 | 味の素株式会社 | 栄養組成物 |
JP5950292B2 (ja) * | 2008-12-05 | 2016-07-13 | 味の素株式会社 | 栄養組成物 |
US9629386B2 (en) | 2008-12-05 | 2017-04-25 | Ajinomoto Co., Inc. | Nutrition composition |
ES2521841A1 (es) * | 2013-05-08 | 2014-11-13 | Instituto De Investigación Sanitaria - Fundación Jiménez Díaz | Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005094813A1 (ja) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5831851B2 (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
JPH0322366B2 (ja) | ||
JPH0811728B2 (ja) | 栄養輸液用アミノ酸溶液、その調製法及び使用法 | |
JP2010180244A (ja) | 肝癌発生・進展抑制剤 | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
KR102007177B1 (ko) | 비만 집중 치료 환자의 비경구 영양 공급 제품 | |
JP5939550B2 (ja) | 酸化型アルブミン低下剤 | |
US20070197647A1 (en) | Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients | |
WO2005094813A1 (ja) | 腎疾患用薬剤 | |
Motil et al. | Complications of essential amino acid hyperalimentation in children with acute renal failure | |
JP4011638B2 (ja) | 経口経腸栄養組成物 | |
JP3908513B2 (ja) | 肝機能改善剤 | |
EP0231768B1 (en) | A composition of amino acids | |
WO2007018278A1 (ja) | 肝癌発生・進展抑制剤 | |
Ballard et al. | Megaloblastic anemia complicating hyperalimentation therapy | |
JPWO2005089743A1 (ja) | 腎性貧血治療剤 | |
CN102600138A (zh) | 透析患者用输液 | |
JP3429327B2 (ja) | 癌用アミノ酸輸液剤 | |
JPH06256186A (ja) | 癌用アミノ酸製剤 | |
JP6169458B2 (ja) | 鉄代謝改善用輸液剤 | |
JPH11209303A (ja) | 腎不全治療薬及び腎不全患者用食品 | |
WO2002074303A1 (fr) | Compositions d'acides amines pour ameliorer l'insuffisance renale | |
JP5076327B2 (ja) | 分岐鎖アミノ酸の心不全適応 | |
Morley | Nutrition and the Kidney in the Elderly Patient | |
JP2012144567A (ja) | 分岐鎖アミノ酸の心不全適応 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511898 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |